News
InteRNA Technologies Secures Final Extension Series A Financing and Strengthens Its Supervisory Board
InteRNA Technologies B.V., a biopharma company engaged in the development of microRNA (miRNA)-based therapeutics for oncology, announces the closing of an equity financing round. This final extension of its Series A was co-led by new investors INKEF Capital and Aglaia Oncology Fund II. Existing shareholders also participated in this round, bringing the total Series A funding to US$ 10.5 million.New Partnership with India Aims to Build Vaccine Manufacturing Network for Hookworm, Other Diseases
The Amsterdam Institute for Global Health and Development (AIGHD) and Sabin Vaccine Institute Product Development Partnership (Sabin PDP) announced a new research and innovation partnership with the Association of Biotechnology Led Enterprises (ABLE) of India on vaccine development for hookworm and other neglected tropical diseases (NTDs).Inventory Dutch Antibiotic Research
Het ministerie van VWS heeft InnoTact Consulting verzocht om een nationale samenwerkingsstructuur uit te werken. Als onderdeel hiervan inventariseren we de Nederlandse onderzoeks- en ontwikkelingsprojecten en programma’s die leiden tot nieuwe antibiotica, alternatieve behandelingen (peptiden, bacteriofagen, vaccins etc) of hiervoor in te zetten technologieën.Johnson & Johnson Announces Start of Clinical Trial of Ebola Vaccine Regimen in Sierra Leone
Johnson & Johnson announced the start of a safety and immunogenicity clinical trial in Sierra Leone of a preventive Ebola vaccine regimen in development at its Janssen Pharmaceutical Companies. Trial recruitment is underway, and the first volunteers have received their initial vaccine dose.Top Sector LSH Innovation Contract 2016-2017
The Top Sector Life Sciences & Health finalised the construction of the Innovation Contract (IC) for 2016-2017. This contract is in line with the formerly published Knowledge & Innovation Agenda (KIA) 2016-2019 and includes an overview of the indicative investments of the sector's stakeholders for the upcoming two years.
Knowledge & Innovation Contract 2016-2017
In dit contract bekrachtigen bedrijven, maatschappelijke instellingen, kennispartijen en overheden hun inzet op de belangrijke innovatiethema’s voor de jaren 2016-2017. Daarmee wordt voortgebouwd op de samenwerking die de afgelopen jaren in gang is gezet.
LSP’s Clemens Van Blitterswijk receives the prestigious Huibregtsen Prize for 2015
Clemens van Blitterswijk, partner at LSP (Life Sciences Partners), the specialist healthcare investment firm, has won the prestigious Huibregtsen Prize 2015 for the development of bone-inducing biomaterials.